CIK 0001621227 · Non-accelerated filer<br>Smaller reporting company
Adaptimmune Therapeutics PLC
Sign in to watch- Ticker
- ADAPY
- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- United Kingdom
- Entity type
- operating
- Phone
- 44 1235 430000
- Business address
- 60 JUBILEE AVENUE, MILTON PARK, ABINGDON, OXFORDSHIRE, United Kingdom
- Former names
- Adaptimmune Ltd
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 10 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-09-01 | Rawcliffe Adrian Chief Executive Officer | Sale | −2,782 | $5.20 | $14K | 3,070 |
| 2021-08-02 | Lunger John Chief Patient Supply Officer | Sale | −2,939 | $3.58 | $11K | 4,873 |
| 2021-07-02 | Bertrand William C JR Chief Operating Officer | Sale | −4,375 | $4.26 | $19K | 7,329 |
| 2021-07-02 | Lunger John Chief Patient Supply Officer | Sale | −1,907 | $4.26 | $8K | 3,170 |
| 2021-07-01 | Behbahani Ali Director | Grant or award · Option to purchase Ordinary Shares | +474,385 | 474,385 | ||
| 2021-07-01 | Zaks Tal Zvi Director | Grant or award · Option to purchase Ordinary Shares | +379,788 | 379,788 | ||
| 2021-07-01 | Alleva Lawrence M Director | Grant or award · Option to purchase Ordinary Shares | +505,918 | 505,918 | ||
| 2021-07-01 | Furey John Director | Grant or award · Option to purchase Ordinary Shares | +379,788 | 379,788 | ||
| 2021-07-01 | Noble James Director | Grant or award · Option to purchase Ordinary Shares | +379,788 | 379,788 | ||
| 2021-07-01 | Sigal Charles Elliott Director | Grant or award · Option to purchase Ordinary Shares | +474,385 | 474,385 | ||
| 2021-07-01 | MOTT DAVID M Director | Grant or award · Option to purchase Ordinary Shares | +579,494 | 579,494 | ||
| 2021-07-01 | Duncan Barbara Gayle Director | Grant or award · Option to purchase Ordinary Shares | +379,788 | 379,788 | ||
| 2021-06-28 | Rawcliffe Adrian Chief Executive Officer | Sale | −2,794 | $4.37 | $12K | 3,058 |
| 2021-06-01 | Alleva Lawrence M Director | Purchase | +12,600 | $0.79 | $10K | 12,600 |
| 2021-03-03 | TAYTON-MARTIN HELEN KATRINA Chief Business Officer | Option exercise | +1,785,000 | $0.16 | $280K | 1,800,000 |
| 2021-01-19 | Norry Elliot Chief Medical Officer | Sale | −2,111 | $5.67 | $12K | 3,539 |
| 2021-01-19 | Lunger John Chief Patient Supply Officer | Sale | −4,358 | $5.67 | $25K | 7,346 |
| 2021-01-19 | Rawcliffe Adrian Chief Executive Officer | Sale | −9,879 | $5.67 | $56K | 13,529 |
| 2021-01-12 | Bertrand William C JR Chief Operating Officer | Sale | −2,234 | $6.15 | $14K | 3,768 |
| 2021-01-12 | Lunger John Chief Patient Supply Officer | Sale | −1,058 | $6.15 | $7K | 1,767 |
Page 11 of 23 · 454 trades